|
1. Biologie
|
|
|
|
|
|
|
2.10 Etiologie - Alcool
|
|
|
Study Causes Splash, but Here’s Why You Should Stay Calm on Alcohol’s Risks [NY Times]
|
|
|
|
|
|
A
chart in the study showed rising risks from alcohol from 0 to 15
drinks. Consider that 15 desserts a day would be bad for you. I am sure
that I could create a chart showing increasing risk for many diseases
from 0 to 15 desserts. This could lead to assertions that “there’s no
safe amount of dessert.” But it doesn’t mean you should never, ever eat
dessert.
|
|
|
|
|
|
|
3.3 Prévention - Vaccins
|
|
|
|
4.9 Dép., diag. & prono. - Sein
|
|
|
A New Way to Detect Breast Cancer [NY Times]
|
|
|
|
|
|
Mr.
Shah and his colleague Matthew Campisi developed iBreastExam, a
battery-operated wireless machine that records variations in breast
elasticity. It’s hand-held and allows health care workers to perform
breast examinations in five minutes, anywhere. Painless and
radiation-free, it provides results just a few minutes after the exam
through a mobile app, which also records patients’ data.
|
|
|
|
|
|
|
5.1 Traitements - Pré-clinique
|
|
|
Stem cells show promise as drug delivery tool for childhood brain cancer [UNC School of Medicine]
|
|
|
|
|
|
For
the study, researchers reprogrammed skin cells into stem cells, and
then genetically engineered them to manufacture a substance that becomes
toxic to other cells when exposed to another drug, called a “pro-drug.”
Inserting the drug-carrying stem cells into the brain of laboratory
models after surgery decreased the size of tumors by 15 times, and
extended median survival in mice by 133 percent. Using human stem cells,
they prolonged life of the mice by 123 percent.
|
|
|
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
Evaluation of Clinical Trial Costs and Barriers to Drug Development [Igea Hub]
|
|
|
|
|
|
In
the last decade, medical researchers have been evaluating more cost
effective ways of conducting clinical trials and to fast-track clinical
translation of new treatments. However, proving clinical effectiveness
of new treatment -in a world of diverse potential patients- is becoming
increasingly complex. Many companies are then faced with the task of
recruiting even more patients at multicenter sites. This automatically
translates to increased costs of clinical trial.
|
|
|
|
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.12.1 Immunothérapies - partenariats
|
|
|
|
5.12.2 Immunothérapies - CAR-T, thérapies cellulaires
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA,...)
|
|
|
|
|
5.6 ESMO
|
|
|
|
6.1 Observation
|
|
|
CDC: Mouth area now most common site of HPV-linked cancer [University of Minnesota]
|
|
|
|
|
|
Cervical
cancer was the most common type of HPV-linked cancer in 1999, with
13,125 cases, while oropharyngeal cancer cases numbered 9,375, with 74%
of them in men. By 2015, oropharyngeal cancer cases outnumbered cervical
cases by 18,917 to 11,788, with 82% (15,479) of the oropharyngeal cases
in males.
|
|
|
|
|
|
|
6.10 Politiques
|
|
|
A no-deal Brexit will betray British science [The Guardian]
|
|
|
|
|
|
The
UK has coordinated more Horizon 2020 projects than any other country to
date, and has a hard-earned reputation for effective project
leadership. In a no-deal Brexit, this leadership role is stone cold
dead. That prospect is impacting projects being prepared right now.
|
|
|
|
|
|
|
|
6.11 Patients
|
|
|
|
6.6 Publications
|
|
|
|
6.7 DMP, Big Data & applis
|
|
|
|
6.9 Controverses
|
|
|